EUVIMEDEUVIMED entdecken
Open Access

Prevalence of Antiphospholipid Antibodies and Association With Incident Cardiovascular Events

Yu Zuo, Sherwin Navaz, Wenying Liang, Chun Li, Colby R Ayers, Christine E Rysenga, Alyssa Harbaugh, Gary L Norman, E Blair Solow, Bonnie Bermas, Oludamilola Akinmolayemi, Anand Rohatgi und 3 weitere

JAMA Network Open · 04.04.2023 · 6 (4) · e236530

DOI: 10.1001/jamanetworkopen.2023.6530 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 04.04.2023. Verfasst von Yu Zuo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Cardiovascular Diseases. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NHLBI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The prevalence of antiphospholipid antibodies (aPL) and their association with future atherosclerotic cardiovascular disease (ASCVD) risk has yet to be thoroughly investigated.

Objective

To determine the association between measurements of aPL at a single time point and ASCVD risk in a diverse population. Design, Setting, and Participants This cohort study measured 8 aPL (anticardiolipin [aCL] IgG/IgM/IgA, anti–beta-2 glycoprotein I [aβ2GPI] IgG/IgM/IgA, and antiphosphatidylserine/prothrombin [aPS/PT] IgG/IgM) by solid-phase assays in plasma from participants of the Dallas Heart Study (DHS) phase 2, a multiethnic, population-based cohort study. Blood samples were collected between 2007 and 2009. The median follow-up was 8 years. Statistical analysis was performed from April 2022 to January 2023. Main Outcomes and Measures Associations of aPL with future ASCVD events (defined as first nonfatal myocardial infarction, first nonfatal stroke, coronary revascularization, or death from cardiovascular cause) were assessed by Cox proportional hazards models, adjusting for known risk factors, medications, and multiple comparisons.

Results

Among the 2427 participants (mean [SD] age, 50.6 [10.3] years; 1399 [57.6%] female; 1244 [51.3%] Black, 339 [14.0%] Hispanic, and 796 [32.8%] White), the prevalence of any positive aPL tested at a single time point was 14.5% (353 of 2427), with approximately one-third of those detected at a moderate or high titer; aCL IgM had the highest prevalence (156 individuals [6.4%]), followed by aPS/PT IgM (88 [3.4%]), aβ2GPI IgM (63 [2.6%]), and aβ2GPI IgA (62 [2.5%]). The IgA of aCL (adjusted hazard ratio [HR], 4.92; 95% CI, 1.52-15.98) and aβ2GPI (HR, 2.91; 95% CI, 1.32-6.41) were independently associated with future ASCVD events. The risk further increased when applying a positivity threshold of at least 40 units (aCL IgA: HR, 9.01 [95% CI, 2.73-29.72]; aβ2GPI IgA: HR, 4.09 [95% CI, 1.45-11.54]). Levels of aβ2GPI IgA negatively correlated with cholesterol efflux capacity ( r = −0.055; P = .009) and positively correlated with circulating oxidized LDL ( r = 0.055; P = .007). aβ2GPI IgA–positive plasma was associated with an activated endothelial cell phenotype as evidenced by increased surface expression of surface E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1. Conclusions and Relevance In this population-based cohort study, aPL detectable by solid-phase assays were present in a substantial proportion of adults; positive aCL IgA and aβ2GPI IgA at a single time point were independently associated with future ASCVD events. Longitudinal studies with serial aPL measurements are needed to further explore these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiphospholipid SyndromeCardiovascular DiseasesFemaleMaleHumansCohort StudiesPrevalenceAntibodies, AntiphospholipidImmunoglobulin MImmunoglobulin AImmunoglobulin G

Substanzen

Antibodies, AntiphospholipidImmunoglobulin MImmunoglobulin AImmunoglobulin G

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor.
  • Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.
  • Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.
  • Headquarters & Technology Center Autoimmunity, Werfen, San Diego, California.
  • Division of Rheumatic Disease, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.
  • Department of Internal Medicine, New York-Presbyterian/Columbia University Irving Medical Center, New York.

Förderung

  • NIAMS NIH HHS
  • NHLBI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Zuo, Y., Navaz, S., Liang, W., Li, C., Ayers, C. R., Rysenga, C. E., Harbaugh, A., Norman, G. L., Solow, E. B., Bermas, B., Akinmolayemi, O., Rohatgi, A., Karp, D. R., Knight, J. S., & de Lemos, J. A. (2023). Prevalence of Antiphospholipid Antibodies and Association With Incident Cardiovascular Events. JAMA Network Open, 6(4), e236530. https://doi.org/10.1001/jamanetworkopen.2023.6530

Vancouver

Zuo Y, Navaz S, Liang W, Li C, Ayers CR, Rysenga CE, et al. Prevalence of Antiphospholipid Antibodies and Association With Incident Cardiovascular Events. JAMA Network Open. 2023;6(4):e236530. doi:10.1001/jamanetworkopen.2023.6530

BibTeX
@article{Zuo2023,
  author = {Zuo, Yu and Navaz, Sherwin and Liang, Wenying and Li, Chun and Ayers, Colby R and Rysenga, Christine E and Harbaugh, Alyssa and Norman, Gary L and Solow, E Blair and Bermas, Bonnie and Akinmolayemi, Oludamilola and Rohatgi, Anand and Karp, David R and Knight, Jason S and de Lemos, James A},
  title = {Prevalence of Antiphospholipid Antibodies and Association With Incident Cardiovascular Events},
  journal = {JAMA Network Open},
  year = {2023},
  volume = {6},
  number = {4},
  pages = {e236530},
  doi = {10.1001/jamanetworkopen.2023.6530}
}
Kostenlos starten →